Table 3.
Sleep parameters mean (SD) measured by actigraphy and polysomnography at each dose of melatonin
| Parameter | 0 mg | 1 mg | 3 mg | p valuea |
|---|---|---|---|---|
| Sleep latency (ACT) | 43.7 (19.6) | 30.8 (15.7) | 26.6 (10.2) | 0.01 |
| Sleep latency (PSG) | 13.4 (13.3) | 43.6 (67.0) | 10.8 (14.8) | 0.35 |
| Sleep duration (ACT) | 421.9 (48.4) | 439.1 (61.3) | 442.8 (48.0) | 0.67 |
| Sleep duration (PSG) | 476 (72.2) | 468.0 (153.8) | 380.4 (187.8) | 0.35 |
| Sleep efficiency (ACT) | 73.3 (5.4) | 74.8 (7.6) | 75.1 (5.0) | 0.09 |
| Sleep efficiency (PSG) | 86.4 (8.4) | 80.6 (22.8) | 72.2 (25.4) | 0.23 |
| WASO (ACT) | 79.8 (27.0) | 83.3 (26.1) | 88.9 (27.0) | 0.21 |
| WASO (PSG) | 44.4 (54.0) | 32.9 (58.0) | 18.6 (20.0) | 0.89 |
Actigraphy parameters were measured based on 2 weeks at 0 mg and 3 weeks at 1 and 3 mg excluding PSG nights; PSG parameters were measured on the night of the serial blood draws
a
Related samples Wilcoxon signed rank test